Novartis Ag (NVS) EBT Margin (2009 - 2025)

Novartis Ag has disclosed EBT Margin across 14 years of filings, most recently posting 32.24% for Q2 2025.

• EBT Margin for Q2 2025 came in at 32.24%, up 154.0% year-over-year; the trailing twelve-month figure through Jun 2025 was 28.08% (up 178.0% YoY), and the FY2025 annual result was 29.99%, up 288.0% from the prior year.
• EBT Margin came in at 32.24% for Q2 2025 at Novartis Ag, up from 28.63% in the prior quarter.
• In the past five years, EBT Margin ranged from a high of 1854.72% in Q4 2022 to a low of 15.98% in Q2 2022.
• The 5-year median for EBT Margin is 31.47% (2024), against an average of 226.09%.
• Across the five-year window, EBT Margin tumbled 200503 bps in 2021 and jumped 183125 bps in 2022, its largest moves.
• Novartis Ag's EBT Margin stood at 23.48% in 2021, then surged by 7799 bps to 1854.72% in 2022, then tumbled by 99 bps to 23.36% in 2023, then climbed by 23 bps to 28.63% in 2024, then advanced by 13 bps to 32.24% in 2025.
• The last three EBT Margin figures came in at 32.24% (Q2 2025), 28.63% (Q4 2024), and 30.7% (Q2 2024), per Business Quant data.